You’ll be alright H - it was good but going over a lot of what we here have discussed many times... and you are one who knows what we have here mate
each interview he needs to assume it’s to new investors and needs to reinforce the key talking points etc - though there is always some new info or small approach adjustment.
- james was tasked with finding homes for these kinds of drugs at Sanofi - we are late in the game - entering GBM agile a pivotal study for FDA approval - it’s any time from now that we partner or even get acquired - much more data coming out
etc etc
it was good and on point but no big new revelation was made
